Determinants of Virological Response After Discontinuation of Nucleoside Analogue Therapy in Hepatitis B Patients

Exclusion Criteria

• •HBeAg positive chronic hepatitis B at the time of NA initiation
• •HBV associated extra hepatic manifestations
• •Documented or suspected hepatocellular carcinoma (HCC)
• •History of decompensated liver disease
• •Compensated cirrhosis defined as:
• •METAVIR liver fibrosis stage 4 on pre-treatment biopsy; OR
• •TLE \> 9.6 kPa at screening
• •Co-infection with HIV,HCV or HDV
• •Latrogenic or disease related immunosuppression (e.g. treatment with systemic glucocorticoids, TNFa-antibodies, and other immunosuppressive drugs)
• •Significant alcohol consumption (\> 30 g/day for women and \> 50 g/day for men)
• •Current known history of cancer within 5 years of screening
• •Pregnant or breast feeding
• •Other known significant liver disease (including but not limited to haemochromatosis, autoimmune hepatitis, alcoholic liver disease)
• •Participation in any other interventional trial
• •Poor Venous access
• •Suspected lack of compliance
• •Any medical or social reason which in the opinion of the investigator would make the subject inappropriate for the study